Oxidative stress in Niemann-Pick disease, type C

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 214-218

  Fu, Rao ^a,b   Yanjanin, Nicole M ^a   Bianconi, Simona ^a   Pavan, William J ^c   Porter, Forbes D ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Coenzyme Q10; Lysosomal storage disease; Neurodegenerative disease; Oxidative stress; Trolox equivalent antioxidant capacity

Indexed keywords

ANTIOXIDANT; UBIDECARENONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; DEGENERATIVE DISEASE; FEMALE; HUMAN; LIPID TRANSPORT; LYSOSOME STORAGE DISEASE; MALE; NIEMANN PICK DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MIDDLE AGED; NIEMANN-PICK DISEASE, TYPE C; OXIDATIVE STRESS; UBIQUINONE;

MUS;

EID: 77957226432     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.06.018     Document Type: Article

References (45)

1. Vanier M.T., Millat G. Niemann-Pick disease type C. Clin. Genet. 2003, 64(4):269-281.
2. Carstea E.D., et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997, 277(5323):228-231.
3. Naureckiene S., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000, 290(5500):2298-2301.
4. Davies J.P., Ioannou Y.A. Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein. J. Biol. Chem. 2000, 275(32):24367-24374.
5. Friedland N., et al. Structure of a cholesterol-binding protein deficient in Niemann-Pick type C2 disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(5):2512-2517.
6. Kwon H.J., et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009, 137(7):1213-1224.
7. Pentchev P.G., et al. The Niemann-Pick C lesion and its relationship to the intracellular distribution and utilization of LDL cholesterol. Biochim. Biophys. Acta 1994, 1225(3):235-243.
8. Zervas M., et al. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 2001, 11(16):1283-1287.
9. Frolov A., et al. NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols. J. Biol. Chem. 2003, 278(28):25517-25525.
10. Schedin S., et al. Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem. 1997, 272(10):6245-6251.
11. Lloyd-Evans E., et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 2008, 14(11):1247-1255.
12. Baudry M., et al. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol. 2003, 184(2):887-903.
13. Wu Y.P., et al. Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol. Genet. Metab. 2005, 84(1):9-17.
14. Griffin L.D., et al. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med. 2004, 10(7):704-711.
15. Jolkkonen M., et al. Muscarinic toxins from the black mamba Dendroaspis polylepis. Eur. J. Biochem. 1995, 234(2):579-585.
16. Zampieri S., et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J. Cell Mol. Med. 2008.
17. Cenedella R.J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009, 44(6):477-487.
18. Fernandez A., et al. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J. Neurosci. 2009, 29(20):6394-6405.
19. Mari M., et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 2006, 4(3):185-198.
20. Yu W., et al. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J. Biol. Chem. 2005, 280(12):11731-11739.
21. Zhang J.R., et al. Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J. Clin. Invest. 2008, 118(6):2281-2290.
22. Kadenbach B., et al. Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic. Biol. Med. 2000, 29(3-4):211-221.
23. Yamamoto Y., Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol. Aspects Med. 1997, 18 Suppl:S79-S84.
24. Ingold K.U., et al. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(1):45-49.
25. Castro I.A., et al. Free radical scavenger and antioxidant capacity correlation of alpha-tocopherol and Trolox measured by three in vitro methodologies. Int. J. Food Sci. Nutr. 2006, 57(1-2):75-82.
26. Yanjanin, N.M., et al., Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 153B(1): p. 132-40.
27. Patterson M.C., et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J. Child Neurol. 2009.
28. Pannu R., et al. A novel role of lactosylceramide in the regulation of lipopolysaccharide/interferon-gamma-mediated inducible nitric oxide synthase gene expression: implications for neuroinflammatory diseases. J. Neurosci. 2004, 24(26):5942-5954.
29. Atkuri K.R., et al. Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. Proc. Natl Acad. Sci. USA 2009, 106(10):3941-3945.
30. Ayaz M., et al. Coenzyme Q(10) and alpha-lipoic acid supplementation in diabetic rats: conduction velocity distributions. Methods Find. Exp. Clin. Pharmacol. 2008, 30(5):367-374.
31. Tiano L., et al. Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects. Biofactors 2008, 32(1-4):161-167.
32. Devi L., et al. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 2006, 26(35):9057-9068.
33. Henchcliffe C., Beal M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4(11):600-609.
34. Sohmiya M., et al. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J. Neurol. Sci. 2005, 228(1):49-53.
35. Steele P.E., et al. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am. J. Clin. Pathol. 2004, 121 Suppl:S113-S120.
36. Ferrante R.J., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22(5):1592-1599.
37. Cooper J.M., et al. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 2008, 15(12):1371-1379.
38. Devi G., et al. A comparison of family history of psychiatric disorders among patients with early- and late-onset Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 2004, 16(1):57-62.
39. Beyer R.E., et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(6):2528-2532.
40. Bowry V.W., et al. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. J. Biol. Chem. 1995, 270(11):5756-5763.
41. Ko D.C., et al. Cell-autonomous death of cerebellar purkinje neurons with autophagy in Niemann-Pick type C disease. PLoS Genet. 2005, 1(1):81-95.
42. Gelsthorpe M.E., et al. Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding. J. Biol. Chem. 2008, 283(13):8229-8236.
43. van Giersbergen P.L., Dingemanse J. Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J. Clin. Pharmacol. 2007, 47(10):1277-1282.
44. Gondre-Lewis M.C., McGlynn R., Walkley S.U. Cholesterol accumulation in NPC1-deficient neurons is ganglioside dependent. Curr. Biol. 2003, 13(15):1324-1329.
45. Patterson M.C., et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007, 6(9):765-772.